Objective: To document the effects of two doses of dexmedetomidine on the induction characteristics and dose requirements of alfaxalone.
Study Design: Randomized controlled clinical trial.
Animals: Sixty one client owned dogs, status ASA I-II.
Methods: Dogs were allocated randomly into three groups, receiving as pre-anaesthetic medication, no dexmedetomidine (D0), 1 μg kg(-1) dexmedetomidine (D1 ) intramuscularly (IM) or 3 μg kg(-1) dexmedetomidine IM (D3). All dogs also received 0.2 mg kg(-1) methadone IM. Level of sedation was assessed prior to induction of anaesthesia. Induction of general anaesthesia was performed with alfaxalone administered intravenously to effect at a rate of 1 mg kg(-1) minute(-1) ; the required dose to achieve tracheal intubation was recorded. Anaesthesia was maintained with isoflurane in oxygen. Cardiopulmonary parameters were recorded throughout the anaesthetic period. Quality of intubation, induction and recovery of anaesthesia were recorded. Quantitative data were compared with one-way anova or Kruskal-Wallis test. Repeated measures were log-transformed and analysed with repeated measures anova (p < 0.05).
Results: Treatment groups were similar for categorical data, with exception of sedation level (p < 0.001). The doses (mean ± SD) of alfaxalone required for intubation were D0 1.68 ± 0.24, D1 1.60 ± 0.36 and D3 1.41 ± 0.43, the difference between D0 and D3 being statistically significant (p = 0.036). Heart and respiratory rates during the anaesthetic period were significantly different over time and between groups (p < 0.001); systolic arterial blood pressure was significantly different over time (p < 0.001) but not between groups (p = 0.833). Induction quality and recovery scores were similar between groups (p = 1.000 and p = 0.414, respectively).
Conclusions And Clinical Relevance: The administration of alfaxalone resulted in a good quality anaesthetic induction which was not affected by the dose of dexmedetomidine. Dexmedetomidine at 3 μg kg(-1) IM combined with methadone provides good sedation and enables a reduction of alfaxalone requirements.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/vaa.12121 | DOI Listing |
Acta Neurochir Suppl
October 2019
Department of Neurosurgery, The Third Xiangya Hospital, Central South University, Changsha, China.
Background: Subarachnoid hemorrhage (SAH) is a severe and emergent cerebrovascular disease, the prognosis of which usually very poor. Microthrombi formation highlighted with inflammation occurs early after SAH. As the main cause of DCI, microthrombosis associated with the prognosis of SAH.
View Article and Find Full Text PDFMacromol Biosci
January 2017
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI, 53705, USA.
Triolimus is a multi-drug loaded polymeric micelle containing paclitaxel (PTX), 17-allylamino-17-demethoxygeldanamycin (17-AAG), and rapamycin (RAP). This study examines the radiosensitizing effect of Triolimus in vitro and in vivo. Radiosensitizing effects of Triolimus on A549 cells are dose dependent and at 2 × 10 m, Triolimus shows significant radiosensitization even at low radiation doses (2 Gy).
View Article and Find Full Text PDFXenobiotica
March 2017
a Epizyme Inc , Cambridge , MA , USA and.
1. The plasma clearance of the first-in-class DOT1L inhibitor, EPZ-5676 (pinometostat), was shown to be markedly lower in human compared to the preclinical species, mouse, rat and dog. 2.
View Article and Find Full Text PDFAims: The primary aim of this study was to describe the pharmacokinetics of total and unbound bupivacaine and ropivacaine following epidural bolus and infusion in neonates and young infants. Secondary aims were to investigate the influence of alpha-1-acid glycoprotein (AAG) on the concentration-time profiles and to determine the efficacy and adverse event profile of the epidural regimen.
Methods/materials: Thirty-one infants aged 40-63 weeks of postmenstrual age (PMA) undergoing hernia repair or abdominal surgery received an epidural injection of 1.
Paediatr Anaesth
September 2004
Department of Anaesthesiology, Universitätsklinikum Mannheim, Mannheim, Germany.
Background: The aims of this study were to evaluate pharmacokinetics, efficacy and safety of ropivacaine in infants aged 0-12 months following a single caudal injection.
Methods: Term ASA I-III patients, scheduled for surgery, with a body weight of > or = 2500 g received a caudal block with ropivacaine 2 mg x ml(-1), 1.0 ml x kg(-1).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!